From what I heard in the interview, Rebecca's comment on scarcity of neurosurgeons was about the trials themselves, not the final product.
Given this scarcity, the trials become not only expensive but logistically challenging to plan and conduct.
Her feeling seems to be that CHM's limited resources are better focused on the other trials... at least for now.
